Ssues were measured using immunohistochemistry and ELISAs. Data are expressed asSsues were measured using immunohistochemistry

May 17, 2018

Ssues were measured using immunohistochemistry and ELISAs. Data are expressed as
Ssues were measured using immunohistochemistry and ELISAs. Data are expressed as the mean ?SEM. For statistical analysis a two-way ANOVA for repeated measurements with appropriate post-hoc comparisons (Student ewman euls) was performed. ACY-241 chemical information Results There were no differences between groups at baseline. All variables remained stable in sham animals throughout the entire experiment. Compared with injured controls, AVP reduced NOx plasma levels (24 hours: 9.5 ?1.2 vs 4.5 ?0.9 ol/l), improved PaO2/FiO2 ratio (24 hours: 214 ?20 vs 431 ?38, each P < 0.001) and decreased the degree of pulmonary edema and airway obstruction. In addition, AVP improved myocardial contractility, as indexed by increased left ventricular stroke work index (24 hours: 52 ?7 vs 87 ?10 g/m/m2). Compared with injured controls, AVP prevented the increase in 3-nitrotyrosine concentrations (lung: 43 ?4 vs 32 ?3 nM; heart: 37 ?5 vs 22 ?3 nM; P < 0.01 each). Conclusion This study suggests that low-dose AVP infusion may be a rational approach to attenuate cardiopulmonary dysfunctions resulting from combined burn and smoke inhalation injury. The effects of AVP in this model may be related to inhibition of the cytotoxic ONOO?Figure 1 (abstract P361)P361 Effects of enalaprilat sodium on plasma NTproANP and NTproBNP levels in healthy volunteersM Heringlake1, B Will1, S Klaus1, H Pagel1, K Wagner1, R Wergeland2, L Bahlmann1 1Universitaet L eck, Germany; 2Rikshospitalet, University of Oslo, Norway Critical Care 2006, 10(Suppl 1):P361 (doi: 10.1186/cc4708) Background The N-terminal prohormones of the A-type and Btype natriuretic peptides (NTproANP and NTproBNP) are increasingly used as humoral markers for myocardial dysfunction in various clinical settings [1]. No data are available on the effects of angiotensin-converting-enzyme inhibition (ACE-I) on the plasma levels of these hormones. Materials and methods Ten healthy males were cross-over and double-blind treated with 20 mg enalaprilat sodium or placebo (t0) following 7 days on a sodium enriched-diet and an induction period of PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/27385778 4 days with increasing doses of enalapril. After 4 hours (t4) 15 PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/25447644 ml/kg NaCl 0.9 was infused over 60 min. Hemodynamics were determined and blood was sampled at t0, t4, t5, t6, t8, and t10 hours. NTproANP and NTproBNP were determined by radioluminescence and electrochemoluminescence immunoassays, respectively. Data were analyzed as raw data and as relative changes in comparison with baseline levels. Results Arterial blood pressure was significantly lower after enalapril treatment during the fourth day of induction and during t0 8 in comparison with control. Raw NT-proANP levels did notchange throughout the observation period; relative NTproANP levels showed a short-lasting increase from t4 to t6 during control and ACE-I (after sodium loading). Raw and relative plasma NTproBNP levels increased from t0 to t10 during placebo and enalapril (P < 0.001). No between-group differences were observed in raw NTproBNP levels, while relative NTproBNP levels were significantly higher after ACE-I in comparison with control at t4 and t5 (Fig. 1). Conclusions This suggests that ACE-I does not affect baseline and stimulated plasma NTproANP levels but augments the reactivity of the BNP system in sodium-loaded healthy individuals. ACE-I may thus interfere with NTproBNP determinations in sodium-retaining states. Reference 1. Hoffmann U, Brueckmann M, Bertsch T, et al.: Increased plasma levels of NT-proANP and NT-proBNP as markers of.